Data may be delayed — last successful sync 2026-09-26 (18 days ago). Figures reflect the most recent completed ingest.
Company profile
Beam Therapeutics Inc.
NASDAQ: BEAM · Healthcare · Biotechnology
#317 of 1,417 Healthcare companies by revenuetop-quartile growth
EA Score
62CFH 65DQ 60GM 54SS 68
v0.1 · 65/100 weight · provisional
↑ filing timeliness, market scale · ↓ growth stability, disclosure history
Methodology →Revenue TTM
$155.5M
Rev growth YoY (TTM)
+158.1%
Net income (FY)
-$80.0M
Employees
540
as of 2026-09-08
Market cap
$3.1B
as of 2026-09-08
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$139.7M$139.7M2025
Net income-$80.0M-$80.0M2025
Operating income-$383.7M-$383.7M2025
Total assets$1.5B$1.5B2025
Liabilities$242.8M$242.8M2025
Equity$1.2B$1.2B2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Beam Therapeutics Inc.’s revenue?
Beam Therapeutics Inc. booked $139.7M in FY2025 revenue, growing 120% year over year — faster than most Healthcare companies we track, at a -57.2% net margin.
Peers · Healthcare
Karyopharm Therapeutics Inc.48DiAnthus Capital Holdings, Inc.46DInfuSystem Holdings, Inc.80B+Spok Holdings, Inc.83B+Quanterix Corporation56CTelesis Bio, Inc.——Neighbors
Middlesex →Key facts
CEOJohn Evans
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: BEAM
Employees540
IPO date2020-02-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.